Phase I trials of BIIB 037 (aducanumab) shows promise in Alzheimers Disease- Biogen

Scientists at Neurimmune have reported results from the Phase 1b PRIME clinical trial of the monoclonal antibody BIIB 037 (aducanumab), from Biogen, in Alzheimers Disease. The report, published in the journal Nature, showed that aducanumab removed amyloid plaques from the brains of patients with early-stage Alzheimer's disease. Importantly, amyloid plaque reductions occurred in both a dose- and time-dependent manner. After one year, in patients receiving aducanumab, the levels of amyloid plaques, visualized using positron emission tomography (PET), were substantially reduced. There was also evidence that aducanumab slowed cognitive decline in these patients.

Importantly, if confirmed by future trials, these results provide compelling support for the hypothesis that amyloid build-up is a key factor in driving cognitive decline in Alzheimer's disease. Aducanumab has been developed in collaboration with the leading pharmaceutical company Biogen, and is the product of Neurimmune's proprietary Reverse Translational Medicine (RTM) technology platform.

See: "The antibody aducanumab reduces A? plaques in Alzheimer�s disease" Jeff Sevigny et al. Nature, 537, 50�56 (01 September 2016) doi:10.1038/nature19323